Restasis (Cyclosporine Ophthalmic) - Current Clinical Trials

Restasis Related Clinical Trials

Study of Two Formulations of Cyclosporine Ophthalmic Emulsion in Healthy Volunteers and in Patients With Dry Eye [Completed]

Safety and Efficacy Study of Cyclosporine Ophthalmic Emulsion in Post-LASIK Patients [Completed]

Efficacy of Cyclosporine Ophthalmic Emulsion in the Treatment of Dry Eye Syndrome in Contact Lens Wearers [Completed]

Safety and Efficacy of Cyclosporine Ophthalmic Emulsion in Patients With Primary Pterygium [Completed]

Physician's Evaluation of Cyclosporine Ophthalmic Emulsion 0.05% [Completed]

Efficacy Study of Cyclosporine Ophthalmic Emulsion in Patients With Dry Eye Disease [Completed]

Efficacy of 0.05 % Cyclosporine Ophthalmic Emulsion Compare With Tear in Meibomian Gland Dysfunction [Completed]

NOVA22007 0.05% and 0.1% Cyclosporine Versus Vehicle for the Treatment of Dry Eye [Completed]

Lotemax® Gel 0.5% and Restasis 0.05% in Subjects With Mild or Moderate Keratoconjunctivitis Sicca [Completed]

Topical Cyclosporine vs. Placebo for Epiphora Associated With Docetaxel [Withdrawn]

Efficacy of Cyclosporine for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy [Completed]

Efficacy and Safety Study of Cyclosporine 0.010% to Treat Atopic Keratoconjunctivitis [Completed]

Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder [Active, not recruiting]

Restasis for Treatment of Brittle Nails [Completed]

Evaluating Safety and Efficacy of FID 112903 Post Discontinuation of Long-term Use of RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05% [Completed]

Topical Cyclosporine Suspension for the Treatment of Brittle Nails [Completed]

Comparison of Effect of Postoperative Cyclosporine A 2% Ophthalmic Emulsion and Betamethasone Eye Drop on Surgical Success of Trabeculectomy Procedure [Completed]

Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye [Completed]

A Phase IV, Randomized, Parallel Group, Investigator-Masked Evaluation of the Effect of Loteprednol Etabonate Ophthalmic Gel 0.5% on the Initiation of Dry Eye Treatment With Restasis® [Withdrawn]

Bromfenac 0.09% vs Ketorolac 0.4% for Cyclosporine Induction Phase [Completed]